CDX-011

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Drug Information

Target Indication

Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CLDX

Celldex Therapeutics, Inc.

Related Pipeline

Glioblastoma

Prurigo Nodularis

Glioblastoma

Advanced Malignancies

Malignant Glioma